Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials

K Reich; A Blauvelt; M Lebwohl; KA Papp; P Rich; B Strober; D De Cuyper; C Madden; L Peterson; V Vanvoorden; RB Warren

doi:10.25251/skin.5.supp.21

K Reich

Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

A Blauvelt

Oregon Medical Research Center, Portland, Oregon, USA

M Lebwohl

Icahn School of Medicine at Mount Sinai, New York, New York, USA

KA Papp

Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada

P Rich

Oregon Dermatology and Research Center, Portland, Oregon, USA

B Strober

Yale University, New Haven, Connecticut, USA; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA

D De Cuyper

UCB Pharma, Brussels, Belgium

C Madden

UCB Pharma, Raleigh, North Carolina, USA

L Peterson

UCB Pharma, Raleigh, North Carolina, USA

V Vanvoorden

UCB Pharma, Brussels, Belgium

RB Warren

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

Keywords

Plaque Psoriasis, Biologic, Bimekizumab, Safety

Abstract

Abstract not available.

References

1. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

2. Papp KA. J Am Acad Dermatol 2018;79:277–86 e10.

Poster PDF

Published

Jan 1, 2021

DOI https://doi.org/10.25251/skin.5.supp.21

How to Cite

Reich, K., Blauvelt, A., Lebwohl, M., Papp, K., Rich, P., Strober, B., De Cuyper, D., Madden, C., Peterson, L., Vanvoorden, V., & Warren, R. (2021). Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal of Cutaneous Medicine, 5(1), s21. https://doi.org/10.25251/skin.5.supp.21

Issue

Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

Section

Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
KA Papp, M Lebwohl, AB Gottlieb, M Sebastian, R Langley, Y Okubo, M Wang, C Cioffi, F Staelens, K Reich, Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
C.E.M. Griffiths, K.A. Papp, M Song, M Miller, Y You, Y-K Shen, C Han, A Blauvelt, Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
CEM Griffiths, KA Papp, M Song, B Randazzo, S Li, YK Shen, C Han, A Blauvelt, Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
PCM van de Kerkhof, K Reich, CL Leonardi, A Blauvelt, NN Mehta, TF Tsai, R You, P Papanastasiou, M Milutinovic, CEM Griffiths, Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
M Lebwohl, M Siegel, L Shankle, L Pisenti, M Yassine, S Van Vorhees, A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
K Gordon, P Foley, JG Krueger, A Pinter, K Reich, R Vender, V Vanvoorden, C Madden, L Peterson, A Blauvelt, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
K Gordon, P Foley, P Rich, K Duffin, A Pinter, CEM Griffiths, M Wang, V Vanvoorden, F Staelens, V Ciaravino, JF Merola, Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
B Strober, JG Krueger, N Magnolo, R Vender, DP Toth, D Thaci, M Wang, C Cioffi, C Madden, RB Warren, Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)